Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Generic-Drug Price Fixing: Is It Happening?

Philip Seo, MD, MHS  |  Issue: May 2018  |  May 17, 2018

I hope that some of those damages may be redirected toward such efforts as the Intermountain Healthcare initiative to bring at least some part of the generic drug industry into the nonprofit arena. Profit surely drives innovation, and I would not begrudge anyone the opportunity to make a buck off their hard work. For drugs that have been around for a generation, however, I think we have earned the right to expect they will remain both available and affordable—and the right to breathe.


Dr. SeoPhilip Seo, MD, MHS, is an associate professor of medicine at the Johns Hopkins University School of Medicine, Baltimore. He is director of both the Johns Hopkins Vasculitis Center and the Johns Hopkins Rheumatology Fellowship Program.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Generic drugs: Questions and answers. U.S. Food and Drug Administration. Updated 2018 Jan 4.
  2. Davit et al. Comparing generic and innovator drugs: A review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009 Oct;43(10):1583–1597.
  3. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA. 2008 Dec 3;300(21):2514–2526.
  4. Generic competition and drug prices. U.S. Food and Drug Administration. Updated 2017 Nov 28.
  5. Generic drug access & savings in the U.S. Association for Accessible Medicines. 2017.
  6. Pear R. Drug company ‘shenanigans’ to block generics come under federal scrutiny. The New York Times. 2018 Apr 15;A20.
  7. Berkrot B. Pharma’s Puerto Rico problems could mean drug shortages: FDA chief. Reuters. 2017 Oct 10.
  8. Gottlieb S. Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to facilitate efficient generic drug review to enhance competition, promote access and lower drug prices (FDA statement). U.S. Food and Drug Administration. 2018 Jan 3.
  9. Abelson R, Thomas K. Fed up with drug companies, hospitals decide to start their own. The New York Times. 2018 Jan 18;B1.
  10. Dafney L. Fair pharma? Intermountain’s new generic drug company. NEJM Catalyst. 2018 Feb 1.
  11. Pear R. Why your pharmacist can’t tell you that $20 prescription could cost only $8. The New York Times. 2018 Feb 24;A12.
  12. Tyrell KA. Arkansas PBM bill: A step in the right direction. ACR@Work. 2018 Apr 12.
  13. Brennan Z. Maryland lawmakers pass generic drug price gouging bill. Regulatory Affairs Professionals Society. 2017 Apr 10.
  14. Part D. Generic drug prices declined overall, but some had extraordinary price increases. U.S. Government Accountability Office. 2016 Aug 12.
  15. Lane C. Probe into generic drug price fixing set to widen. Morning Edition. NPR. 2018 Mar 7.
  16. Diamond ML. Eaton drug execs will tell all in price-fixing case. Asbury Park Press. 2017 May 24.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:generic competitiongeneric drug makersnot-for-profit generic drugmaker

Related Articles

    Mark Cuban: Mixing Up the Pharmaceutical Landscape

    April 7, 2023

    The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…

    Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

    June 14, 2017

    While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

    The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

    June 15, 2017

    Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

    Psoriatic Arthritis Drugs at a Glance, 2023

    April 21, 2023

    Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences